Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + epirubicin
- Development stage
- Phase 3
- Lead developer
- Groupe Hospitalier Diaconesses Croix Saint-Simon
- Modality
- Small Molecules
- Administration
- Intravenous, Intraperitoneal
01
Overview
This combination chemotherapy regimen consists of cisplatin and epirubicin, specifically investigated by Groupe Hospitalier Diaconesses Croix Saint-Simon in the CHIMOVIP randomized phase II trial (NCT01505140). Cisplatin is a platinum-based small molecule that acts as a DNA alkylating agent, forming inter- and intra-strand cross-links that inhibit DNA replication and transcription, leading to apoptosis. Epirubicin is an anthracycline small molecule that intercalates into DNA and inhibits DNA topoisomerase II, further disrupting DNA synthesis and repair. This specific protocol evaluates the efficacy of intraperitoneal (IP) cisplatin combined with intravenous (IV) epirubicin in patients with advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer, particularly following optimal cytoreductive surgery.
- Other names
- cisplatin + epirubicin regimenCHIMOVIP regimenIP cisplatin + IV epirubicin
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cisplatin + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + epirubicin.